News Search Results
May 05, 2025, 17:15 ET Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
May 05, 2025, 12:47 ET Lilly declares second-quarter 2025 dividend
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 05, 2025, 11:20 ET Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy
ATLANTA, May 5, 2025 /PRNewswire/ -- Odylia Therapeutics, a nonprofit (501(c)3) biotechnology company dedicated to advancing treatments for rare diseases, today announced its latest pipeline project: a unique and innovative co-development
More news about: Odylia Therapeutics
May 05, 2025, 10:57 ET Breakthrough Alzheimer's Vaccine Duvax Secures $3 Million NIH Grant to Launch U.S. Clinical Trials
Nuravax Inc., a biotechnology company pioneering immunotherapy for neurodegenerative disorders, has been awarded a $3 million grant from the National
More news about: Nuravax Inc
May 05, 2025, 09:00 ET Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
LinkedIn. About Optieum BiotechnologiesOptieum Biotechnologies Inc. is a cutting-edge biotechnology company dedicated to engineering hope for patients through the development of next-generation CAR-T cell therapies. At the heart of Optieum's innovation
More news about: Genezen
May 05, 2025, 08:08 ET Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
YORK, May 5, 2025 /PRNewswire/ -- IGI, a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track
More news about: Ichnos Glenmark Innovation
May 05, 2025, 08:00 ET Matica Biotechnology and Texas A&M's NCTM Form Strategic Partnership to Deliver End-to-End Support for Cell and Gene Therapy Innovators
COLLEGE STATION, Texas, May 5, 2025 /PRNewswire/ -- Matica Biotechnology, a specialized contract development and manufacturing organization (CDMO) for cell and gene therapies (CGT), has entered into a strategic partnership
More news about: Matica Biotechnology, Inc.
May 05, 2025, 08:00 ET Orna Therapeutics Announces Presentation at the American Society of Gene and Cell Therapy Annual Meeting Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases
WATERTOWN, Mass., May 5, 2025 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat autoimmune and oncology diseases, today announced an upcoming presentation
More news about: Orna Therapeutics
May 05, 2025, 08:00 ET Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
May 5, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory
More news about: Spyre Therapeutics, Inc.
May 05, 2025, 08:00 ET Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon Biologics Ltd.
May 05, 2025, 07:57 ET Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
YORK, May 5, 2025 /PRNewswire/ -- IGI, a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track
More news about: Ichnos Glenmark Innovation
May 05, 2025, 07:30 ET Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
May 05, 2025, 05:45 ET Shareholders that lost money on Sana Biotechnology, Inc.(SANA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
May 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: Gross Law Firm
May 05, 2025, 02:25 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive
More news about: THE ROSEN LAW FIRM, P. A.
May 05, 2025, 01:48 ET BPIPOとDCBがLINK-Jと提携、東京で初の再生医療投資イベントを開催
Corporationは、変性疾患に対する幹細胞治療に力点を置く展示を行いました。同社のHong-Lin Su会長は次のように述べています。「当社の3-in-1ソリューション（多血小板フィブリン、PBMC、成長因子）は、変形性関節症をコントロールするために物理的、化学的な成分を組み合わせたものです。」同様に、Ascension Medical Biotechnology Co., Ltd. は、一貫したGMP製造と臨床試験の実績を強調しました。「私たちは100種類以上のエクソソームを誘導することができ、さまざまな病気をターゲットにしています」と会長のRichard Shieh博士は説明しています。 がん治療分野では、AngenMed
More news about: BPIPO
May 03, 2025, 08:00 ET A Masterpiece in Metal and Light: Groundbreaking Ceremony for the CMU Museum of Fine Arts Marks a Milestone in Taiwan's Architectural History
Chang-Hai Tsai expressed his ambition to extend the university's contributions beyond its achievements in education, medicine, and biotechnology: "Through architecture and art, and through the hand of a master architect, we hope to offer the world a glimpse of Taiwan's
More news about: China Medical University Hospital
May 02, 2025, 16:05 ET Spyre Therapeutics Announces Grants of Inducement Awards
May 2, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience
More news about: Spyre Therapeutics, Inc.
May 02, 2025, 10:30 ET Life Science Analytics Market worth $68.81 billion by 2030 11.4% CAGR | MarketsandMarkets™
Pacific is fostering scientific innovation and technological advancement. Furthermore, increased direct investments from pharmaceutical and biotechnology companies in Europe and North America are anticipated to boost the adoption of
More news about: MarketsandMarkets
May 02, 2025, 10:00 ET Lilly to participate in Bank of America Securities 2025 Healthcare Conference
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 02, 2025, 09:01 ET University of California, Irvine wins Alamo Cup at Nightwing-Sponsored 2025 National Collegiate Cyber Defense Championship
competitions of its kind, this year's NCCDC tasked competitors with the scenario of managing, operating, and defending the network infrastructure of a biotechnology firm – responding to customers and routine business tasks while fending off attacks from hackers. Akshay Rohatgi,
More news about: Nightwing Group, LLC
May 02, 2025, 07:30 ET Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the 14th International Bone Morphogenetic
More news about: OSR Holdings Inc.
May 02, 2025, 06:30 ET Immunic to Participate in Scientific and Industry Conferences in May
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
May 02, 2025, 05:45 ET Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
May 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
May 01, 2025, 21:56 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and reminds investors of the May 20, 2025 deadline to seek the
More news about: Faruqi & Faruqi, LLP
May 01, 2025, 18:00 ET Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics